A Case of Metastatic Thymoma Responsive to Treatment With 177Lu-DOTATATE

Reut Halperin*, Damien Urban, Amit Tirosh

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


We describe a case of a 74-year-old woman with germline BRCA2 mutation, with an incidental diagnosis of metastatic thymoma presenting as a mediastinal mass with cardiac muscle and lymph node involvement. Despite surgical and radiotherapy treatment, there was marked advancement with new lung and liver metastases. All lesions demonstrated 68Ga-DOTATATE PET/CT uptake, and the patient received 4 peptide receptor radionuclide therapy cycles with 177Lu-DOTATATE, with pronounced reduction in the size of the liver, cardiac, and pleural lesions. This is the first case to demonstrate partial response to peptide receptor radionuclide therapy in metastatic thymoma, thus suggesting possible treatment option to refractory and advancing metastatic thymoma.

Original languageEnglish
Pages (from-to)E190-E192
JournalClinical Nuclear Medicine
Issue number4
StatePublished - 1 Apr 2023


  • PRRT
  • peptide receptor radionuclide therapy
  • somatostatin
  • thymoma


Dive into the research topics of 'A Case of Metastatic Thymoma Responsive to Treatment With 177Lu-DOTATATE'. Together they form a unique fingerprint.

Cite this